We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vac... Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.12 | -5.28634361233 | 2.27 | 2.32 | 1.9 | 81858 | 2.09180312 | CS |
4 | 0.15 | 7.5 | 2 | 2.7 | 1.71 | 236476 | 2.17094714 | CS |
12 | -1.44 | -40.1114206128 | 3.59 | 5.75 | 1.71 | 270191 | 2.77849144 | CS |
26 | -8.73 | -80.2389705882 | 10.88 | 12.12 | 1.71 | 197834 | 4.15294585 | CS |
52 | -22.85 | -91.4 | 25 | 30.44 | 1.71 | 183299 | 11.51112547 | CS |
156 | -3.85 | -64.1666666667 | 6 | 40.98 | 1.71 | 151545 | 13.65734566 | CS |
260 | -3.85 | -64.1666666667 | 6 | 40.98 | 1.71 | 151545 | 13.65734566 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions